(Circulation. 1996;94:673-682.)
© 1996 American Heart Association, Inc.
Articles |
Changes in Early and Late Diastolic Filling Patterns Induced by Long-term Adrenergic ß-Blockade in Patients With Idiopathic Dilated Cardiomyopathy
the Divisions of Cardiology (B.A., A°.H., F.W.) and Clinical Physiology (K.C., I.W.), Sahlgrenska University Hospital, Goteborg, Sweden; the Department of Cardiology (A.d.L.), Ospedale Maggiore and University, Trieste, Italy; the Division of Cardiology (S.E.W.), Beth Israel Hospital, Boston, Mass; the Department of Medicine (F.G.), Zentralklinikum, Augsburg, Germany; the Department of Medicine (A.W.), Norrland University Hospital, Umea°, Sweden; and the Department of Medicine (S.P.), University of Lund (Sweden).
Correspondence to Dr Bert Andersson, Kardiologdivisionen, Sahlgrenska Sjukhuset, S-413 45 Goteborg, Sweden. E-mail bert.andersson@hjl.gu.se.
Background ß-Blockers have been used in patients with idiopathic dilated cardiomyopathy to improve cardiac performance and theoretically would be beneficial to diastolic function. However, there are few reports on changes in diastolic function during chronic pharmacological treatment of congestive heart failure.
Methods and Results The present study was a substudy in the international Metoprolol in Dilated Cardiomyopathy Trial. Transmitral Doppler echocardiography was used to evaluate diastolic function in 77 patients randomly assigned to placebo (n=37) or metoprolol (n=40). The patients were treated for 12 months. Changes in Doppler flow variables in the metoprolol group implied a less restrictive filling pattern, expressed as an increase in E-wave deceleration time (placebo, 185±126 to 181±64 ms; metoprolol, 152±63 to 216±78 ms; P=.01, placebo versus metoprolol). Maximal increase in deceleration time had occurred by 3 months, whereas systolic recovery was achieved gradually and maximal effect was seen by 12 months of treatment. Although deceleration time was correlated to heart rate at baseline, changes in deceleration time were not significantly correlated to changes in heart rate during treatment.
Conclusions During the first 3 months of treatment, maximal effects on diastolic variables were reached, whereas the most prominent effect on systolic function was seen late in the study. It is suggested that effects on diastolic filling account for subsequent later myocardial systolic recovery. The E-wave deceleration time, which in recent studies has been shown to be a powerful predictor of survival, was significantly improved in the metoprolol-treated patients.
Key Words: heart failure • cardiomyopathy • systole • diastole • echocardiography • receptors, adrenergic, beta
This article has been cited by other articles:
 |
|
 |
|
  S. Haney, D. Sur, and Z. Xu Diastolic Heart Failure: A Review and Primary Care Perspective J Am Board Fam Med, May 1, 2005; 18(3): 189 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Danchin If current inhibition with ivabradine: further perspectives Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G52 - G56. [Abstract] [PDF]
|
|
|
|
 |
|
 B Andersson, B Gruner Svealv, M Scharin Tang, and R Mobini Longitudinal myocardial contraction improves early during titration with metoprolol CR/XL in patients with heart failure Heart, January 1, 2002; 87(1): 23 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Andersson, F Waagstein, K Caidahl, I Eurenius, M S. Täng, and R Wikh Early changes in longitudinal performance predict future improvement in global left ventricular function during long term beta adrenergic blockade Heart, December 1, 2000; 84(6): 599 - 605. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Willenheimer, E. Rydberg, L. Oberg, S. Juul-Moller, and L. Erhardt ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function Eur. Heart J., November 2, 1999; 20(22): 1647 - 1656. [Abstract] [PDF]
|
|
|
|
 |
|
 J. E. Sanderson, S. K. W. Chan, G. Yip, L. Y. C. Yeung, K. W. Chan, K. Raymond, and K. S. Woo Beta-blockade in heart failure: A comparison of carvedilol with metoprolol J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1522 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kim, W. H. Devlin, S. K. Das, J. Petrusha, D. Montgomery, and M. R. Starling Effects of {beta}-Adrenergic Blocking Therapy on Left Ventricular Diastolic Relaxation Properties in Patients With Dilated Cardiomyopathy Circulation, August 17, 1999; 100(7): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Andersson, S.-O. Stromblad, M. Lomsky, and F. Waagstein Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol Eur. Heart J., April 2, 1999; 20(8): 575 - 583. [Abstract] [PDF]
|
|
|
|
 |
|
 UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ, September 12, 1998; 317(7160): 713 - 720. [Abstract] [Full Text]
|
|
|
|
|
|
J E Sanderson, S K W Chan, C M Yu, L Y C Yeung, W M Chan, K Raymond, K W Chan, and K S Woo beta Blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol Heart, January 1, 1998; 79(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wachtell, J. N. Bella, J. Rokkedal, V. Palmieri, V. Papademetriou, B. Dahlof, T. Aalto, E. Gerdts, and R. B. Devereux Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Circulation, March 5, 2002; 105(9): 1071 - 1076. [Abstract] [Full Text] [PDF]
|
|